Latest news with #ThibautMongon
Yahoo
7 days ago
- Business
- Yahoo
S&P 500 Gains & Losses Today: Dollar General Stock Soars as Discount Retailer Posts Solid Results
The S&P 500 advanced 0.6% on Tuesday, June 3, 2025, as a report showing a surprise increase in job openings last month signaled labor-market resilience. Dollar General shares skyrocketed after the discount retailer beat quarterly estimates, raised its outlook, and expressed confidence in its capacity to mitigate tariff impacts. Shares of Kenvue lost ground as the consumer health supplier's CEO discussed softness in seasonal U.S. equities indexes finished higher after data from the Bureau of Labor Statistics showed an unexpected uptick in job openings in April, although several economists cautioned that tariffs could weigh on jobs growth as the year advances. The S&P 500 ended Tuesday's session 0.6% higher. The Dow added 0.5%. Strength among semiconductor firms and the rest of the tech sector helped lift the Nasdaq 0.8%. Read Investopedia's full daily markets roundup here. Dollar General (DG) shares surged 16%, chalking up the S&P 500's top daily performance after the discount retailer topped quarterly sales and profit estimates and boosted its full-year outlook. The company anticipated that it should be able to mitigate most tariff-related cost pressure but expressed uncertainty around the possible impact on consumer spending trends. Analysts have said that dollar stores could be poised to benefit as consumers trade down in the current environment. Shares of Dollar Tree (DLTR), set to report its own results Wednesday morning, were up 6%. Shares of ON Semiconductor (ON) jumped 11% after the company's top executive discussed expectations for a recovery in demand. In a presentation at the Bank of America Technology Conference, Onsemi CEO Hassane El-Khoury pointed to signs of recovery in the company's industrials market, its second largest, as well as indications that the automotive market could see a bottom in the second quarter. First Solar (FSLR) stock bounced 6.5% higher on Tuesday, reversing losses posted in the prior session. Shares of companies in the renewable energy space have come under pressure since the House passed a reconciliation bill that calls for the elimination of numerous clean energy initiatives and the Department of Energy cancelled an array of related grants. Mizuho analysts boosted their price target on the stock. Crude oil futures prices extended their recent string of gains, bolstered by increasing geopolitical tensions, including an escalation of the war in Ukraine and an uncertain outlook for a U.S.-Iran nuclear deal. The price uptick helped lift oil and gas stocks, with shares of exploration and production firm APA Corp. (APA) gaining 5.4%. Shares of Kenvue (KVUE), the consumer health company that spun off from Johnson & Johnson (JNJ) in 2023, dropped 6.2%, the furthest of any S&P 500 stock. Kenvue CEO Thibaut Mongon suggested that a lagging transition from spring into winter had contributed to soft seasonal demand for allergy and sun protection products. FactSet Research Systems (FDS) shares sank 4.8% after the financial data and software provider announced that Sanoke Viswanathan, formerly an executive at JPMorgan Chase (JPM), would take the reins as CEO starting in September. Current CEO Phil Snow is set to retire and exit his position on FactSet's board of directors at that time. Read the original article on Investopedia Sign in to access your portfolio
Yahoo
03-06-2025
- Business
- Yahoo
Kenvue Leads S&P 500 Decliners as CEO Points to Seasonal Demand Challenges
Shares of Kenvue (KVUE) led S&P 500 decliners Tuesday after the consumer health giant's chief executive indicated the firm faces seasonal demand challenges. Speaking at Deutsche Bank's dbAccess Global Consumer Conference, Kenvue CEO Thibaut Mongon highlighted the importance of seasonality for its allergy products, like Benadryl and Zyrtec. "We saw a longer winter, so winter pushed spring into later in Q2," Mongon said, according to a transcript provided by AlphaSense. "So we see that on allergy where we saw a later start to the season, and so far, it's below last year." Mongon also noted similar seasonal troubles for its sun protection brands, like Neutrogena and Aveeno. "In sun, we see more or less the same. Late start to the season year-to-date behind last year, but the season has not really started for recreational sun, and Memorial Day weekend was just a few days ago," Mongon said. "It was not great, as you and I could see. But, again, we are just at the beginning of the season. So it's too early to read the season. It will certainly impact Q2." Kenvue shares were down more than 7% in recent trading. With today's sharp declines, the stock's year-to-date gains stand at less than 3%. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-06-2025
- Business
- Yahoo
Kenvue Debuts on Fortune 500 List
SUMMIT, N.J., June 02, 2025--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our Kenvuers, while also further propelling our desire to become the undisputed global leader in consumer health. We are honored to join this elite group of companies and look forward to continuing our journey of growth and impact." Operating in over 165 countries worldwide, Kenvue is comprised of a curated portfolio of Essential Health, Self Care, and Skin Health & Beauty brands reaching approximately 1.2 billion people daily. Its global workforce of more than 20,000 purpose-led, values-based Kenvuers are driven to make a meaningful impact on the health of people and the planet. By combining the power of science with deep human insights and cutting-edge technology, Kenvue is poised to use its size and scale as a Fortune 500 company to take a leadership role in the wellness revolution - placing its products and solutions at the center of everyday care rituals, today and into the future. Now in its 71st year, the Fortune 500 is Fortune magazine's annual list of the 500 largest U.S. companies ranked by total revenues for their respective fiscal years. The list is compiled using the most recent revenue figures and includes both public and private companies. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at View source version on Contacts Investor Relations: Sofya TsinisKenvue_IR@ Media Relations: Melissa WittMedia@ Sign in to access your portfolio
Yahoo
02-06-2025
- Business
- Yahoo
Kenvue Debuts on Fortune 500 List
SUMMIT, N.J., June 02, 2025--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our Kenvuers, while also further propelling our desire to become the undisputed global leader in consumer health. We are honored to join this elite group of companies and look forward to continuing our journey of growth and impact." Operating in over 165 countries worldwide, Kenvue is comprised of a curated portfolio of Essential Health, Self Care, and Skin Health & Beauty brands reaching approximately 1.2 billion people daily. Its global workforce of more than 20,000 purpose-led, values-based Kenvuers are driven to make a meaningful impact on the health of people and the planet. By combining the power of science with deep human insights and cutting-edge technology, Kenvue is poised to use its size and scale as a Fortune 500 company to take a leadership role in the wellness revolution - placing its products and solutions at the center of everyday care rituals, today and into the future. Now in its 71st year, the Fortune 500 is Fortune magazine's annual list of the 500 largest U.S. companies ranked by total revenues for their respective fiscal years. The list is compiled using the most recent revenue figures and includes both public and private companies. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at View source version on Contacts Investor Relations: Sofya TsinisKenvue_IR@ Media Relations: Melissa WittMedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
02-06-2025
- Business
- Business Wire
Kenvue Debuts on Fortune 500 List
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. 'Being named to the Fortune 500 list marks a significant milestone for Kenvue,' said Thibaut Mongon, Chief Executive Officer. 'Recognitions like this validate the hard work and dedication of our Kenvuers, while also further propelling our desire to become the undisputed global leader in consumer health. We are honored to join this elite group of companies and look forward to continuing our journey of growth and impact.' Operating in over 165 countries worldwide, Kenvue is comprised of a curated portfolio of Essential Health, Self Care, and Skin Health & Beauty brands reaching approximately 1.2 billion people daily. Its global workforce of more than 20,000 purpose-led, values-based Kenvuers are driven to make a meaningful impact on the health of people and the planet. By combining the power of science with deep human insights and cutting-edge technology, Kenvue is poised to use its size and scale as a Fortune 500 company to take a leadership role in the wellness revolution - placing its products and solutions at the center of everyday care rituals, today and into the future. Now in its 71st year, the Fortune 500 is Fortune magazine's annual list of the 500 largest U.S. companies ranked by total revenues for their respective fiscal years. The list is compiled using the most recent revenue figures and includes both public and private companies. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at
